Alzamend Neuro, Inc. (ALZN): Nasdaq/NYSE listing notice — Alzamend Neuro receives Nasdaq deficiency notice for bid price below $1.00

Alzamend Neuro, Inc.

Received Nasdaq deficiency letter on Jan 30, 2023 for bid price below $1.00 for 30 consecutive days.
Has 180 calendar days (until July 31, 2023) to regain compliance by closing at $1.00 for 10 consecutive business days.
May request an additional 180-day compliance period if it meets other listing standards.
No immediate effect on listing; common stock continues trading on Nasdaq under symbol ALZN.
Company intends to monitor bid price and evaluate options to regain compliance, but cannot assure success.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Alzamend Neuro, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

January 30, 2023, Alzamend Neuro, Inc. (the “Company”) received a notice in the form of a letter (“Deficiency Letter”) from the Listing Qualifications Staff of the Nasdaq stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company’s common stock had closed below $1.00 per share for the previous 30 consecutive business days. In accordance with Nasdaq listing rule 5810(c)(3)(A), the Company has 180 calendar days, or until July 31, 2023, to regain compliance. The Deficiency Letter states that to regain compliance, the bid price for the

View on SEC.gov

Browse all listing & compliance notices →

Alzamend Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001214659-23-001612

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.